HHS's proposed interim access policy uses enforcement discretion to assure specialty compounding pharmacies that they will not face regulatory action for producing certain popular peptides, including BPC-157

From the articleTrump Administration Advances Plan for Peptides Favored by RFK Jr.Also in US FDA takes step to change peptide compounding policy | Reuters, Trump administration advances plan for peptide drugs favored by RFK Jr.